NASDAQ:MGNXMacroGenics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding MacroGenics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $27.79 +1.12 (+4.20 %) (As of 08/13/2020 01:08 PM ET) Add Compare Share Today's Range$26.74Now: $27.79▼$27.7950-Day Range$25.26MA: $27.83▼$31.5152-Week Range$4.04Now: $27.79▼$32.18Volume4,442 shsAverage Volume1.64 million shsMarket Capitalization$1.50 billionP/E RatioN/ADividend YieldN/ABeta2.75 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media MacroGenics, Inc., a biopharmaceutical company, discovers and develops antibody-based therapeutics for the treatment of cancer in the United States. Its pipeline of immuno-oncology product candidates includes Margetuximab, a monoclonal antibody, which is in Phase III clinical trial that targets HER2-expressing tumors, such as various breast and gastroesophageal cancers. The company is also developing Flotetuzumab, a DART molecule that recognizes CD123 and CD3; MGA012, an anti-PD-1 monoclonal antibody, which inhibits programmed cell death protein 1 (PD-1); MGD013, a monoclonal antibody that targets the immune checkpoints PD-1 and lymphocyte-activation gene 3; MGD019, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; and Enoblituzumab, a monoclonal antibody that targets B7-H3. In addition, the company is developing MGD009, a DART molecule that targets B7-H3 expressed on tumor cells and CD3; MGC018, an antibody drug conjugate, which targets solid tumors expressing B7-H3; and MGD007, a DART molecule, which targets glycoprotein A33 and CD3; and MGD014, a DART molecule that targets virus-infected cells. It has strategic collaborations with Incyte Corporation; Les Laboratoires Servier and Institut de Recherches Servier; and Zai Lab Limited. MacroGenics, Inc. was founded in 2000 and is headquartered in Rockville, Maryland.Read More Beat the Market (BTM) Rank™ 2.3 Analyst's Opinion Consensus RatingMacroGenics has received a consensus rating of Buy. The company's average rating score is 2.64, and is based on 11 buy ratings, 1 hold rating, and 2 sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $29.92, MacroGenics has a potential upside of 8.9% from its current price of $27.47.Amount of Analyst CoverageMacroGenics has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.5 Community Rank Outperform VotesMacroGenics has received 367 “outperform” votes. (Add your “outperform” vote.)Underperform VotesMacroGenics has received 371 “underperform” votes. (Add your “underperform” vote.)Community SentimentMacroGenics has received 50.27% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about MacroGenics and other stocks. Vote “Outperform” if you believe MGNX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe MGNX will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldMacroGenics does not currently pay a dividend.Dividend GrowthMacroGenics does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, MacroGenics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $411,330.00 in company stock.Percentage Held by InsidersOnly 9.00% of the stock of MacroGenics is held by insiders.Percentage Held by Institutions91.25% of the stock of MacroGenics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for MacroGenics are expected to grow in the coming year, from ($3.47) to ($2.10) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of MacroGenics is -8.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of MacroGenics is -8.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMacroGenics has a P/B Ratio of 5.83. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 2.3Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.29 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:MGNX Previous Symbol CUSIPN/A CIK1125345 Webwww.macrogenics.com Phone301-251-5172Debt Debt-to-Equity Ratio0.10 Current Ratio5.67 Quick Ratio5.67Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$64.19 million Price / Sales23.43 Cash FlowN/A Price / Cash FlowN/A Book Value$4.71 per share Price / Book5.90Profitability EPS (Most Recent Fiscal Year)($3.16) Net Income$-151,810,000.00 Net Margins-214.06% Return on Equity-72.15% Return on Assets-53.05%Miscellaneous Employees364 Outstanding Shares54,117,000Market Cap$1.50 billion Next Earnings Date11/4/2020 (Estimated) OptionableOptionable $27.79 +1.12 (+4.20 %) (As of 08/13/2020 01:08 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive MGNX News and Ratings via Email Sign-up to receive the latest news and ratings for MGNX and its competitors with MarketBeat's FREE daily newsletter. MacroGenics (NASDAQ:MGNX) Frequently Asked Questions How has MacroGenics' stock been impacted by COVID-19 (Coronavirus)? MacroGenics' stock was trading at $6.49 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, MGNX stock has increased by 328.2% and is now trading at $27.79. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of MacroGenics? 14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MacroGenics in the last year. There are currently 2 sell ratings, 1 hold rating and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for MacroGenics. When is MacroGenics' next earnings date? MacroGenics is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020. View our earnings forecast for MacroGenics. How were MacroGenics' earnings last quarter? MacroGenics Inc (NASDAQ:MGNX) released its earnings results on Thursday, July, 30th. The biopharmaceutical company reported ($0.94) EPS for the quarter, missing analysts' consensus estimates of ($0.92) by $0.02. The biopharmaceutical company earned $20.26 million during the quarter, compared to analysts' expectations of $14.19 million. MacroGenics had a negative return on equity of 72.15% and a negative net margin of 214.06%. View MacroGenics' earnings history. What price target have analysts set for MGNX? 14 equities research analysts have issued twelve-month price objectives for MacroGenics' shares. Their forecasts range from $8.00 to $50.00. On average, they anticipate MacroGenics' stock price to reach $29.92 in the next year. This suggests a possible upside of 7.7% from the stock's current price. View analysts' price targets for MacroGenics. Has MacroGenics been receiving favorable news coverage? Media headlines about MGNX stock have been trending extremely negative this week, InfoTrie Sentiment Analysis reports. InfoTrie identifies negative and positive media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. MacroGenics earned a coverage optimism score of -4.1 on InfoTrie's scale. They also gave news articles about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the company's share price in the near future. View the latest news about MacroGenics. Are investors shorting MacroGenics? MacroGenics saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 4,430,000 shares, an increase of 54.9% from the April 30th total of 2,860,000 shares. Based on an average daily trading volume, of 2,940,000 shares, the days-to-cover ratio is currently 1.5 days. Approximately 10.0% of the company's shares are short sold. View MacroGenics' Short Interest. Who are some of MacroGenics' key competitors? Some companies that are related to MacroGenics include Mirati Therapeutics (MRTX), Myokardia (MYOK), Ultragenyx Pharmaceutical (RARE), United Therapeutics (UTHR), Zai Lab (ZLAB), HUTCHISON CHINA/S (HCM), Schrodinger (SDGR), Allakos (ALLK), Blueprint Medicines (BPMC), Arrowhead Pharmaceuticals (ARWR), Evotec (EVTCY), FibroGen (FGEN), Legend Biotech (LEGN), HYPERA S A/S (HYPMY) and Amicus Therapeutics (FOLD). View all competitors. What other stocks do shareholders of MacroGenics own? Based on aggregate information from My MarketBeat watchlists, some companies that other MacroGenics investors own include AbbVie (ABBV), Exelixis (EXEL), Gilead Sciences (GILD), NVIDIA (NVDA), Sangamo Therapeutics (SGMO), TG Therapeutics (TGTX), Incyte (INCY), Sorrento Therapeutics (SRNE), Bausch Health Companies (BHC) and Karyopharm Therapeutics (KPTI). Who are MacroGenics' key executives? MacroGenics' management team includes the following people: Dr. Scott Koenig, CEO, Pres & Director (Age 67)Mr. James Karrels, Sr. VP, CFO & Sec. (Age 52)Dr. Ezio Bonvini, Sr. VP of Research & Chief Scientific Officer (Age 65)Mr. Eric Blasius Risser, Sr. VP of Bus. Devel. & Portfolio Management and Chief Bus. Officer (Age 46)Dr. Jon M. Wigginton, Sr. VP of Clinical Devel. & Chief Medical Officer (Age 57) What is MacroGenics' stock symbol? MacroGenics trades on the NASDAQ under the ticker symbol "MGNX." Who are MacroGenics' major shareholders? MacroGenics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Wasatch Advisors Inc. (4.27%), Rhenman & Partners Asset Management AB (1.37%), Candriam Luxembourg S.C.A. (0.95%), Macquarie Group Ltd. (0.78%), Goldman Sachs Group Inc. (0.70%) and Bank of New York Mellon Corp (0.39%). Company insiders that own MacroGenics stock include Eric Blasius Risser, Jeffrey Stuart Peters, Matthew K Fust and Thomas Spitznagel. View institutional ownership trends for MacroGenics. Which institutional investors are selling MacroGenics stock? MGNX stock was sold by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB, Wasatch Advisors Inc., Candriam Luxembourg S.C.A., Principal Financial Group Inc., Virtus ETF Advisers LLC, California Public Employees Retirement System, State of Wisconsin Investment Board, and UBS Group AG. Company insiders that have sold MacroGenics company stock in the last year include Eric Blasius Risser, and Thomas Spitznagel. View insider buying and selling activity for MacroGenics. Which institutional investors are buying MacroGenics stock? MGNX stock was bought by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Assenagon Asset Management S.A., Macquarie Group Ltd., Barclays PLC, Vident Investment Advisory LLC, Vident Investment Advisory LLC, Trexquant Investment LP, and Aigen Investment Management LP. View insider buying and selling activity for MacroGenics. How do I buy shares of MacroGenics? Shares of MGNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is MacroGenics' stock price today? One share of MGNX stock can currently be purchased for approximately $27.79. How big of a company is MacroGenics? MacroGenics has a market capitalization of $1.50 billion and generates $64.19 million in revenue each year. The biopharmaceutical company earns $-151,810,000.00 in net income (profit) each year or ($3.16) on an earnings per share basis. MacroGenics employs 364 workers across the globe. What is MacroGenics' official website? The official website for MacroGenics is www.macrogenics.com. How can I contact MacroGenics? MacroGenics' mailing address is 9704 MEDICAL CENTER DRIVE, Rockville MD, 20850. The biopharmaceutical company can be reached via phone at 301-251-5172. This page was last updated on 8/13/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
